Moxonidine may increase the hypotensive activities of Nisoldipine. The therapeutic efficacy of Moxonidine can be decreased when used in combination with Clomipramine. Moxonidine may increase the hypotensive activities of Niguldipine. The risk or severity of adverse effects can be increased when Moxonidine is combined with Nifedipine. Moxonidine may increase the hypotensive activities of Enalapril. The risk or severity of adverse effects can be increased when Moxonidine is combined with Isosorbide Mononitrate. Moxonidine may increase the hypotensive activities of Captopril. Moxonidine may increase the hypotensive activities of Tolazoline. Moxonidine may increase the hypotensive activities of Polythiazide. Milnacipran may decrease the antihypertensive activities of Moxonidine. Barbexaclone may increase the hypotensive activities of Moxonidine. Moxonidine may increase the hypotensive activities of Lercanidipine. Moxonidine may increase the hypotensive activities of BQ-123. Moxonidine may increase the hypotensive activities of Hydrochlorothiazide. Moxonidine may increase the hypotensive activities of Metipranolol. Moxonidine may increase the hypotensive activities of Manidipine. The risk or severity of adverse effects can be increased when Bupivacaine is combined with Moxonidine. Desvenlafaxine may decrease the antihypertensive activities of Moxonidine. Moclobemide may increase the hypotensive activities of Moxonidine. Bosentan may increase the hypotensive activities of Moxonidine. Moxonidine may increase the atrioventricular blocking (AV block) activities of Acebutolol. Moxonidine may increase the atrioventricular blocking (AV block) activities of Bevantolol. Moxonidine may increase the hypotensive activities of Theodrenaline. Moxonidine may increase the hypotensive activities of Bimatoprost. Moxonidine may increase the atrioventricular blocking (AV block) activities of Atenolol. Moxonidine may increase the atrioventricular blocking (AV block) activities of Bucindolol. Moxonidine may increase the atrioventricular blocking (AV block) activities of Labetalol. The risk or severity of adverse effects can be increased when Moxonidine is combined with Methyclothiazide. Venlafaxine may decrease the antihypertensive activities of Moxonidine. Moxonidine may increase the hypotensive activities of Selexipag. Moxonidine may increase the hypotensive activities of Urapidil. The risk or severity of adverse effects can be increased when Moxonidine is combined with Canagliflozin. The therapeutic efficacy of Moxonidine can be decreased when used in combination with Mianserin. Moxonidine may increase the hypotensive activities of Bendroflumethiazide. The risk or severity of adverse effects can be increased when Desflurane is combined with Moxonidine. Moxonidine may increase the hypotensive activities of Naftopidil. Moxonidine may increase the atrioventricular blocking (AV block) activities of Propranolol. The risk or severity of adverse effects can be increased when Moxonidine is combined with Nesiritide. Pentoxifylline may increase the hypotensive activities of Moxonidine. Moxonidine may increase the hypotensive activities of Cicletanine. Moxonidine may increase the hypotensive activities of Ketanserin. Moxonidine may increase the atrioventricular blocking (AV block) activities of Esmolol. Moxonidine may increase the hypotensive activities of Epoprostenol. The risk or severity of adverse effects can be increased when Moxonidine is combined with Ropivacaine. The risk or severity of adverse effects can be increased when Imidapril is combined with Moxonidine. Brofaromine may increase the hypotensive activities of Moxonidine. Harmaline may increase the hypotensive activities of Moxonidine. Moxonidine may increase the hypotensive activities of Perindopril. Toloxatone may increase the hypotensive activities of Moxonidine. Moxonidine may increase the hypotensive activities of Macitentan. The risk or severity of adverse effects can be increased when Moxonidine is combined with Sevoflurane. Hydralazine may increase the hypotensive activities of Moxonidine. Moxonidine may increase the hypotensive activities of Rescinnamine. Moxonidine may increase the hypotensive activities of Cryptenamine. Methylphenidate may decrease the antihypertensive activities of Moxonidine. Trans-2-Phenylcyclopropylamine may increase the hypotensive activities of Moxonidine. Guanfacine may increase the hypotensive activities of Moxonidine. The risk or severity of adverse effects can be increased when Moxonidine is combined with Aldesleukin. The therapeutic efficacy of Moxonidine can be decreased when used in combination with Dosulepin. Moxonidine may increase the hypotensive activities of Fenoldopam. Procarbazine may increase the hypotensive activities of Moxonidine. Moxonidine may increase the hypotensive activities of Spirapril. Hydracarbazine may increase the hypotensive activities of Moxonidine. Moxonidine may increase the hypotensive activities of Vinpocetine. Benmoxin may increase the hypotensive activities of Moxonidine. Moxonidine may increase the hypotensive activities of Ticrynafen. The risk or severity of adverse effects can be increased when Moxonidine is combined with Isoxsuprine. The risk or severity of adverse effects can be increased when Moxonidine is combined with Streptokinase. The risk or severity of adverse effects can be increased when Moxonidine is combined with Levobunolol. Moxonidine may increase the hypotensive activities of Enalaprilat. Moxonidine may increase the atrioventricular blocking (AV block) activities of Arotinolol. Moxonidine may increase the atrioventricular blocking (AV block) activities of Celiprolol. The risk or severity of adverse effects can be increased when Moxonidine is combined with Propofol. The risk or severity of adverse effects can be increased when Moxonidine is combined with Ropinirole. Trimethaphan may increase the hypotensive activities of Moxonidine. Moxonidine may increase the hypotensive activities of Phenoxybenzamine. The risk or severity of adverse effects can be increased when Morphine is combined with Moxonidine. Moxonidine may increase the hypotensive activities of Temocapril. The risk or severity of adverse effects can be increased when Moxonidine is combined with Sodium Nitrite. The therapeutic efficacy of Moxonidine can be decreased when used in combination with Esmirtazapine. Moxonidine may increase the hypotensive activities of Hydroflumethiazide. Moxonidine may increase the hypotensive activities of Aliskiren. Phenobarbital may increase the hypotensive activities of Moxonidine. Iloprost may increase the hypotensive activities of Moxonidine. The risk or severity of adverse effects can be increased when Moxonidine is combined with Tamsulosin. Moxonidine may increase the hypotensive activities of Dihydralazine. The risk or severity of adverse effects can be increased when Amiodarone is combined with Moxonidine. Primidone may increase the hypotensive activities of Moxonidine. Moxonidine may increase the hypotensive activities of Metolazone. Mebanazine may increase the hypotensive activities of Moxonidine. Moxonidine may increase the hypotensive activities of Bretylium. Amobarbital may increase the hypotensive activities of Moxonidine. The therapeutic efficacy of Moxonidine can be decreased when used in combination with Amitriptyline. Moxonidine may increase the atrioventricular blocking (AV block) activities of Bisoprolol. The risk or severity of adverse effects can be increased when Carbetocin is combined with Moxonidine. Moxonidine may increase the orthostatic hypotensive activities of Levodopa. The risk or severity of adverse effects can be increased when Moxonidine is combined with Nabilone. The therapeutic efficacy of Moxonidine can be decreased when used in combination with Nortriptyline. The risk or severity of adverse effects can be increased when Moxonidine is combined with Empagliflozin. Moxonidine may increase the hypotensive activities of Candesartan. Moxonidine may increase the atrioventricular blocking (AV block) activities of Nebivolol. Moxonidine may increase the hypotensive activities of Moexipril. Nicorandil may increase the hypotensive activities of Moxonidine. Brimonidine may increase the antihypertensive activities of Moxonidine. The risk or severity of adverse effects can be increased when Bortezomib is combined with Moxonidine. Avanafil may increase the antihypertensive activities of Moxonidine. Moxonidine may increase the atrioventricular blocking (AV block) activities of Betaxolol. The risk or severity of adverse effects can be increased when Moxonidine is combined with Dinutuximab. The risk or severity of adverse effects can be increased when Moxonidine is combined with Sacubitril. Moxonidine may increase the atrioventricular blocking (AV block) activities of Nadolol. Moxonidine may increase the hypotensive activities of Trandolapril. Yohimbine may decrease the antihypertensive activities of Moxonidine. Prazosin may increase the hypotensive activities of Moxonidine. Moxonidine may increase the hypotensive activities of Eprosartan. The risk or severity of adverse effects can be increased when Moxonidine is combined with Azilsartan medoxomil. Moxonidine may increase the hypotensive activities of Torasemide. Methylphenobarbital may increase the hypotensive activities of Moxonidine. The risk or severity of adverse effects can be increased when Moxonidine is combined with Rotigotine. Moxonidine may increase the hypotensive activities of Sitaxentan. Bethanidine may increase the hypotensive activities of Moxonidine. The risk or severity of adverse effects can be increased when Moxonidine is combined with Spironolactone. Tranylcypromine may increase the hypotensive activities of Moxonidine. The risk or severity of adverse effects can be increased when Moxonidine is combined with Isosorbide Dinitrate. Tadalafil may increase the antihypertensive activities of Moxonidine. Moxonidine may increase the hypotensive activities of Guanabenz. Moxonidine may increase the hypotensive activities of Quinapril. Moxonidine may increase the hypotensive activities of Lacidipine. The therapeutic efficacy of Moxonidine can be decreased when used in combination with Doxepin. Moxonidine may increase the atrioventricular blocking (AV block) activities of Practolol. Mecamylamine may increase the hypotensive activities of Moxonidine.